Estradiol improves genital herpes vaccine efficacy in mice

Jeffry W. Pennock, Rachael Stegall, Brent Bell, Gracie Vargas, Massoud Motamedi, Gregg Milligan, Nigel Bourne

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Herpes Simplex Virus type 2 causes genital herpes but is frequently transmitted asymptomatically; therefore, a prophylactic vaccine is desirable. A candidate vaccine in clinical trials has only shown efficacy in preventing disease in women. Using this subunit vaccine candidate, we were able to demonstrate infection prophylaxis, improved disease prevention and modulated antibody production by complimenting vaccination with estradiol in our murine model. Findings of estradiol-enhanced vaccine efficacy are the first of their kind using a vaccine of this type and have potential clinical relevance to the development of other vaccines and our understanding of gender differences in vaccine efficacy.

Original languageEnglish (US)
Pages (from-to)5830-5836
Number of pages7
JournalVaccine
Volume27
Issue number42
DOIs
StatePublished - Sep 25 2009

    Fingerprint

Keywords

  • Estradiol
  • Herpes Simplex Virus Vaccines
  • Herpesvirus 2
  • Human

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this